Compare Hut 8 Corp (HUT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Organon & Co. Common Stock — how do they compare? Hut 8 Corp trades at $69.83 (market cap $9.23B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Hut 8 Corp is far larger — about 2.6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 12 Days and Organon & Co. Common Stock for 0 Days on average.
| HUT | OGN | |
|---|---|---|
Market Cap | $9.23B | $3.61B |
Volume | 12,843,584 | 1,808,049 |
Sector | Financials | Health |
52-Week High | $133.02 | $13.81 |
52-Week Low | $33.76 | $5.70 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $16.67B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $83.61, down 1.91% on the day, amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 with a negative net income margin of 188.59%, though revenue grew to $235.12 million. Recent news highlights a $1.07 billion credit facility and positive analyst coverage, with 16 of 17 analysts rating it a buy and a consensus price target of $163.62.
The outlook is mixed: strong analyst sentiment and AI infrastructure growth potential contrast with persistent losses and high valuation ratios. Key risks include execution on profitability and sensitivity to sector volatility. The stock offers upside if operational improvements materialize but remains speculative given current financials.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
